Psychedelic Research and Access in
Indonesia
Indonesia is currently a low-signal country page in Blossom. Blossom does not currently link this page to psychedelic clinical trials, stakeholders, or events, so it should be read as a database placeholder rather than a mature research profile.
Data updated
Key Insights
A concise view of the policy, research, access, and stakeholder details shaping psychedelic medicine inIndonesia.
- 1
Blossom currently tracks no country-linked psychedelic clinical trials for Indonesia.
- 2
Blossom currently tracks no linked psychedelic stakeholders or events for Indonesia.
- 3
No verified country-specific psychedelic access pathway is recorded in this lightweight page content.
- 4
Future updates should prioritise verified trial registrations, regulator or health-ministry sources, and locally based organisations before adding more detailed claims.
Research and Access Snapshot
Blossom currently tracks no country-linked psychedelic clinical trials for Indonesia, but the page does include 1 stakeholder.
Blossom has not linked country-level trial records yet. Treat this as a coverage gap, not proof that no local policy discussion, care, or informal activity exists.
- Active trials
- 0
- Total trials
- 0
- Stakeholders
- 1
- Events
- 0
None marked active
No linked trials
Linked organisations
No linked events
Top Compounds
Linked country trials do not show a leading compound yet.
Top Study Topics
Linked country trials do not show a leading study topic yet.
Medical Access
Indonesia permits licensed medical use of ketamine (as an approved anesthetic) and has a registered esketamine product (Spravato) with BPOM marketing authorization; both are available only through regulated medical channels and are not routinely reimbursed by public insurance for psychiatric indications. All classical psychedelic compounds requested (psilocybin, MDMA, DMT, 5-MeO-DMT, ayahuasca, mescaline, 2C-X) are controlled or treated as illegal under Indonesian narcotics/psikotropika regulation and enforcement, with no routine medical reimbursement...
Regulatory Status
No country-specific psychedelic access review has been completed for Indonesia. Readers should not infer legal medical availability, reimbursement, or private clinical access from this placeholder; any access question should be checked compound by compound against current local law and medicines regulation.
Country Details
- Region
- Asia
- Last updated
- 4 May 2026
Country Report
Medical Only (Private)Medical Access
Indonesia permits licensed medical use of ketamine (as an approved anesthetic) and has a registered esketamine product (Spravato) with BPOM marketing authorization; both are available only through regulated medical channels and are not routinely reimbursed by public insurance for psychiatric...
Open access guide →Pro Scorecard
Country Scorecard
Compare evidence, access, payment, delivery, local ecosystem, and review confidence for Indonesia.
Open scorecard →Psychedelic Stakeholders in Indonesia
Organisations, sponsors, clinics, and research groups connected to psychedelic science in Indonesia.